Engine Biosciences is a technology-enabled drug discovery company that leverages its proprietary platform to discover and develop new therapeutics. The company integrates biology and technology to map disease circuitry and identify potential drug candidates more efficiently.

Engine Biosciences

MOMA Therapeutics focuses on discovering the next generation of precision medicines by targeting the molecular machines underlying human disease.

MOMA Therapeutics

Prenosis develops precision medicine tools and implements them in real time for acute care settings, focusing on personalizing healthcare based on individual biology. They leverage their Immunix precision medicine platform and have created the FDA authorized Sepsis ImmunoScore.

Prenosis

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies.  We are actively applying the platform internally and with partners across a range of disease indications.

In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Polaris Partners

EDBI

Seeds Capital

ClavystBio

Invus

Coronet Ventures

WI Harper Group

6 Dimensions Capital

Baidu Ventures

Vectr

Nest.Bio Ventures

Goodman Capital

DHVC

Engine Bio is honored to be recognised by Singapore Minister of Trade and Industry Gan Kim Yong for our work to pioneer Al-enabled therapeutics and biomarkers for precision medicine. We are very encouraged by our progress and strong supporters, and we are motivated to keep pushing to deliver impact in healthcare and pharmaceuticals!

(See 13:40 for Minister Gan’s remarks on Engine Bio):

Jeffrey Lu, CEO and co-founder of precision medicines company Engine Biosciences, foresaw "accelerating adoption of Al in biopharma R&D across the value chain. Not only has the 2023 Al boom opened the world's eyes dramatically, application-specific tools that have been built rigorously over the past several years in uses cases like small-molecule screening, target selection, protein design, and patient stratification are reaching greater maturity in technology validation and operational deployment."

Thank you Minister Gan Kim Yong and Ministry of Trade and Industry (Singapore)  for giving us the privilege of hosting you and your colleagues from Enterprise Singapore  and Singapore Economic Development Board (EDB) at our Silicon Valley office!  We enjoyed discussing the opportunities around #precisionmedicine, and Engine Biosciences’ approach by identifying targets, drugs, and biomarkers coming out of our R&D efforts in both Singapore and California.

Metric
Company Name	Engine Biosciences	MOMA Therapeutics	Prenosis
Symbol
MSH ID	COM:ENGINEBIO	COM:MOMATX	COM:PRENOSIS
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	SG	US	US
Stage
Employee Count	37
Website	enginebio.com	momatx.com	prenosis.com
LinkedIn	engine-biosciences		prenosis
Founders

Metric
Market Cap	132.36M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	47.32
28-Day Growth Score	54.60
90-Day Growth Score	50.39
365-Day Growth Score	6.51

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ENGINEBIO

Engine Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue